AbbVie Inc. may so far have been playing on the fringes of the Indian market, but its planned $63bn acquisition of Allergan PLC will give it a market-leading presence in the ophthalmology segment in the country and offers significant potential to expand the Botox business, among other growth avenues.
Unusually, AbbVie does not sell its crown jewel Humira (adalimumab) at all in India and only has a small basket...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
